FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not FDA Roundup: Oncology Drug Approvals in 2026 Cancer Therapy Advisor RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs BREAKING NEWS: FDA Announces Change in Status of 12 Peptides. For future updates like this, education, training, and support, visit the ssrpinstitute.org and explore what the SSRP community has to offer. Links